JVM Wins Six-Year Patent Dispute
JVM, a global leading company in the field of automated medication dispensing, has protected its proprietary core technology rights after a six-year legal battle. The Seoul Central District Court ruled on July 16 that company C, a domestic automated dispensing equipment manufacturer, infringed on JV
JVM, a global leader in automated medication dispensing, has secured its core technology rights following a six-year legal dispute. On July 16, Seoul Central District Court ruled that domestic automated dispensing equipment manufacturer, company C, had infringed on JVM’s patent for an automated medication packaging device. The lawsuit, initiated in 2020, was a result of JVM's objection to company C's unauthorized use of its patented technology.
JVM, an affiliate of Hanmi Science, sought to prohibit patent infringement and claim damages to safeguard its core patent. The case saw intense hearings through the Patent Court and the Supreme Court. Despite company C's strong counterargument of non-infringement and a request for patent invalidation, the higher courts affirmed the validity of JVM's patent.
The ruling emphasized that actual infringement occurred, leading to a compensation obligation. JVM is currently expanding its business by supplying automated medication dispensing solutions worldwide, while Hanmi Pharm handles overseas operations. JVM CEO Kim Sang-wook highlighted the importance of protecting new technology value with legitimate rights and promised to strengthen its global market competitiveness through proprietary intellectual property.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
